The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Alemtuzumab in T-cell Prolymphocytic Leukemia

Anti-CD52 antibody for an aggressive mature T-cell leukemia

Written by: Saygı Hospital Health Guide Editorial Board
Published:

This content is for general information; please consult your physician for diagnosis and treatment.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Alemtuzumab in T-cell Prolymphocytic Leukemia?

T-cell prolymphocytic leukemia is a rare mature T-cell malignancy with marked lymphocytosis, hepatosplenomegaly, skin and serous infiltration, and a poor prognosis without intensive treatment. CD52 is expressed at high density on leukemic cells, making it an ideal target.

Alemtuzumab is given intravenously over a dose-escalation period followed by maintenance until best response. Complete remission rates exceed sixty percent in chemotherapy-naive disease, but durable cure requires allogeneic transplantation in eligible patients.

Treatment causes profound and prolonged lymphocyte depletion, raising the risk of cytomegalovirus reactivation, fungal infection, and other opportunistic disease. Antiviral and antifungal prophylaxis along with weekly cytomegalovirus monitoring are mandatory throughout therapy and during recovery.

Symptoms

Marked lymphocytosis with prolymphocyte morphology
Hepatosplenomegaly and generalized lymphadenopathy
Skin infiltration with rash or nodules
Serous effusions and bone marrow failure
Rapid clinical course without treatment

Risk Factors

Older adult age and male predominance
Ataxia telangiectasia mutated gene aberrations
TCL1A or MTCP1 oncogene activation
History of chest radiation or chronic immune stimulation
Coexisting autoimmune lymphoproliferative features

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • When unexplained marked lymphocytosis is detected
  • When rapidly enlarging spleen or lymph nodes appear
  • When skin nodules or generalized rash develop
  • When recurrent infections suggest immune compromise
  • When transplant evaluation is needed for fit patients

Treatment Methods

01
Intravenous alemtuzumab with dose escalation
02
Cytomegalovirus surveillance with weekly polymerase chain reaction
03
Prophylaxis against herpes virus and Pneumocystis
04
Allogeneic stem cell transplantation in eligible cases
05
Salvage chemotherapy with pentostatin or bendamustine
06
Supportive transfusion and growth factor support
07
Multidisciplinary review with hematology and infectious disease

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.